Year All202420232022202120202019 Jan 02, 2024 Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference Dec 01, 2023 Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement Nov 28, 2023 Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement Nov 28, 2023 Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement Nov 12, 2023 Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia Nov 07, 2023 Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results Oct 31, 2023 Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3 Oct 23, 2023 Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia Sep 26, 2023 Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023 Sep 21, 2023 Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Dec 01, 2023 Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
Nov 28, 2023 Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
Nov 28, 2023 Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Nov 12, 2023 Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
Nov 07, 2023 Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
Oct 31, 2023 Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
Oct 23, 2023 Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
Sep 26, 2023 Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023
